alnylam
This role involves developing and applying advanced in vitro cellular models to support the discovery and optimization of novel delivery strategies for RNAi therapeutics. The candidate will evaluate ligand-mediated delivery, receptor biology, and cellular uptake across multiple therapeutic areas while collaborating with internal teams and external partners.
Headquarters
Cambridge, Massachusetts, United States
Company Size
1001-5000 employees
Founded
2002
Alnylam is a biopharmaceutical company that has pioneered RNA interference (RNAi) therapeutics, an innovative class of medicines that treats diseases by silencing the genes that cause or contribute to them. The company develops RNAi-based medicines targeting both rare and prevalent diseases across multiple therapeutic areas, with approved products and a robust investigational pipeline. Driven by science and inspired by patients, Alnylam is committed to delivering transformational medicines that address diseases at their genetic source.
Headquarters
San Francisco, CA
Company Size
201-500 employees
Founded
2018
Industry
Technology
Glassdoor Rating
4.2 / 5
Sarah Johnson
Chief Executive Officer
Michael Chen
Chief Technology Officer
Emily Williams
VP of Engineering
David Rodriguez
VP of Product
Jessica Thompson
Chief Financial Officer
Andrew Park
VP of Sales
View leadership team, funding history,
and employee contacts for alnylam.
Right around the average for this role
Scientist - Cell Biology - BioTDR
Eli Lilly and Company
Scientist, Bioscience – Cell & Mechanistic Biology
AstraZeneca
Laboratory Technician Cell Biology
Humanitas MICE
Postdoctoral Researcher: Precision Delivery of RNA Therapeutics
ionis
Intern – Cell Biology (6 Month Contract)
Monte Rosa Therapeutics, Inc
Senior Scientist to Principal Scientist, in vitro Biology
Structure Therapeutics